Back to results
US 2004/0082638 A1Published application
Compounds, compositions and methods
AssigneeCytokinetics, Inc.
InventorsAndrew McDonald, Gustave Bergnes, Bainian Feng, David J. Morgans JR., Steven David Knight, Kenneth A. Newlander, Dashyant Dhanak, Christopher A. Brook
Life of this patent
Estimating the term…
Abstract
Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.
Claims67
A compound having the structure:
- 49
- wherein:
- R1 is chosen from hydrogen, optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaryl-, and optionally substituted heteroaralkyl-;
- R2 and R2′ are independently chosen from hydrogen, optionally substituted alkyl-, optionally substituted alkoxy, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaryl-, and optionally substituted heteroaralkyl;
- or R2 and R2′ taken together form an optionally substituted 3- to 7-membered ring;
- R12 is selected from the group consisting of optionally substituted imidazolyl, optionally substituted imidazolinyl, —NHR4;
- —N(R4)(COR3);
- —N(R4)(SO2R3a);
- and —N(R4)(CH2R3b);
- R3 is chosen from hydrogen, optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaryl-, optionally substituted heteroaralkyl-, R15O— and R17—NH—;
- R3a is chosen from optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaryl-, optionally substituted heteroaralkyl-, and R17—NH—;
- R3b is chosen from hydrogen, optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaryl-, and optionally substituted heteroaralkyl;
- R4 is chosen from hydrogen, optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted hetercyclyl-, and optionally substituted heteroaralkyl-;
- R5, R6, R7 and R8 are independently chosen from hydrogen, acyl, optionally substituted alkyl-, optionally substituted alkoxy, halogen, hydroxyl, nitro, cyano, dialkylamino, alkylsulfonyl-, alkylsulfonamido-, alkylthio-, carboxyalkyl-, carboxamido-, aminocarbonyl-, optionally substituted aryl and optionally substituted heteroaryl;
- and
- R15 is chosen from optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaryl-, and optionally substituted heteroaralkyl-,
- R17 is hydrogen, optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaryl-, or optionally substituted heteroaralkyl-, including single stereoisomers, mixtures of stereoisomers;
- a pharmaceutically acceptable salt of a compound of Formula I;
- a pharmaceutically acceptable solvate of a pharmaceutically acceptable solvate of a compound of Formula I;
- or a pharmaceutically acceptable solvate of a pharmaceutically acceptable salt of a compound of Formula I.
17 more elements
The use, in the manufacture of a medicament for treating cellular proliferative disease, of a compound according to any one of claims 1-66, or a pharmaceutically acceptable salt or solvate thereof
Dependencies are inferred from the claim text.